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ABSTRACT
This review article aims at presenting the main considerations on kidney transplantation 
in HIV-positive patients. Over last decade, after the advent of highly active antiretroviral 
therapy (HAART), life expectancy in patients infected with the human immunodefi-
ciency virus (HIV) has changed significantly, with a marked decrease in morbidity and 
mortality rates in this population. In this setting, the numbers of HIV-positive patients 
with end-stage kidney disease requiring dialysis is progressively increasing. In view of 
this new reality, kidney transplantation, once absolutely contraindicated in such patients, 
became an alternative as renal replacement therapy. Issues about the use of immunosup-
pressive agents in this group of patients and their potential action in increasing HIV 
replication, besides the risk of opportunistic infections and neoplasm development, are 
widely discussed. However, clinical experience in this field shows that using these drugs 
in seropositive patients seems to be safe, even with reports of antiretroviral action of 
some immunosuppressant drugs. Nevertheless, there are few transplantation reports in 
this population. In summary, literature data suggests that kidney transplantation, fol-
lowing specific selection criteria, seems to be a safe alternative as kidney replacement 
therapy in this group.
Keywords: HIV; kidney transplantation; kidney chronic disease; highly active antiretro-
viral therapy; immunosuppression.
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INTRODUCTION
Over last decade, after the advent of highly active antire-
troviral therapy (HAART), the life expectancy in patients 
infected by the human immunodeficiency virus (HIV) has 
changed significantly, with a marked decrease in morbidi-
ty and mortality rates in this population1. Chronic diseases 
have become part of HIV infection natural history in this 
new setting and thus therapeutic management definition 
for these cases has assumed substantial relevance.
In clinical practice, chronic kidney disease prevalen-
ce in HIV-infected patients has increased progressively. 
Chronic kidney disease may develop as a clinical course 
and treatment complication in HIV-seropositive patients 
and may independently aThect these patients, similarly to 
what happens in general population. Currently, chronic 
kidney disease impacts significantly the clinical course in 
HIV-positive patients1. HIV-related kidney disease is the 
third cause of end-stage renal disease occurring among 
African-Americans in the United States2. HAART therapy 
introduction has also increased life expectancy in HIV-
-positive patient undergoing dialysis3. Currently there are 
about 500 HIV-positive patients receiving renal replace-
ment therapy in Brazil according to Sociedade Brasileira de 
Nefrologia data4.
In view of this new reality, kidney transplantation, 
once absolutely contraindicated in such patients, is now 
considered an alternative renal replacement therapy5. The 
main considerations about kidney transplantation in HIV-
-positive patients will be shown in this chapter.
HIV AND KIDNEY TRANSPLANTATION
Given the significant increase in HIV-positive patients’ 
survival after HAART era, kidney transplantation has 
been considered an alternative treatment in choric kid-
ney disease in this population. However, many safety- and 
ethics-related questions about organ transplantation in se-
ropositive patients have been raised.
Questions about living donors and allocation criteria 
from deceased donors to the patients are still under dis-
cussion6. Organ allocation from HIV-positive deceased 
donors to seropositive patients has been used in some stu-
dies, but cases of superinfection have been reported and 
this practice has been abandoned7.
Kidney transplantation from living donors can be per-
formed in HIV-positive patients. However, donors are 
recommended to be informed that organ transplantation 
in HIV-infected patients is a recent alternative therapy in 
clinical practice8.
Another preoccupant aspect concerning transplan-
tations in this patient group is the need for using immu-
nosuppressive  drugs with the  possible action to increase 
HIV replication, besides the risk of opportunistic infec-
tions and neoplasm development. Clinical experience in 
this field, however, shows that the use of these drugs in 
seropositive patients appears to be safe. The main aspects 
concerning kidney transplantation in this population are 
introduced as follows.
KIDNEY TRANSPLANTATION – PRE-HAART ERA
Before  the advent of HAART era, reports about HIV-po-
sitive patient kidney transplantation were limited to either 
isolated case reports or small numbers of patients. One of 
the first publications was released in the early 90s by the 
University of Minnesota, reviewing 11 HIV-positive pa-
tients undergoing kidney transplantation. Results showed 
a 36% mortality rate. One patient died from sepsis two 
months after the transplantation and three patients deve-
loped AIDS and died within 13 months. The graft survival 
rate in 30 months was 54%9. Time to progression to AIDS 
was evaluated by Tkazis et al. in three HIV-positive pa-
tient groups with the objective to study immunosuppres-
sion impact on kidney transplantation in HIV-infected 
patients: kidney transplanted patients (n = 25), hemophi-
liacs (n = 42), and patients infected after blood transfusion 
(n = 28). There was a trend to earlier AIDS development 
(15 months) in transplanted patients (16%) than in the two 
other groups. However, from the 15th month on, the trend 
to AIDS development was the same in the three groups, re-
aching statistical significance from de fifth-year follow-up10.
The largest kidney transplantation in positive HIV 
review over the pre-HAART period was obtained from 
USRDS (United States Renal Data System) data, analyzing 
kidney transplantations performed between 1987 and 
1997. The results showed worse patient survival rate in 
the fifth year post-transplantation (71% vs 78% in control 
group) and kidney graft (44% vs 61% in control group). In 
multivariate analysis, HIV infection was listed as indepen-
dent mortality factor for recipients from deceased donors, 
as well as for graft loss11. These results substantiated the 
indication restriction of kidney transplantation in HIV-
-positive patients.
KIDNEY TRANSPLANTATION – POST-HAART ERA
In the late 90s,  with the advent of HAART era, there was 
a great improvement in morbidity and mortality related to 
HIV-positive patients. This improvement also mirrored in 
mortality rates for HIV-positive patients on dialysis, which 
were significantly reduced, coming to equalize the morta-
lity rate in HIV-seronegative patients in dialysis programs. 
The survival rate for HIV-positive patients on dialysis rai-
sed from 56% (before 1990) to 74% (late 90s)12.
These results led to a re-evaluation of kidney trans-
plantation as treatment option in HIV-positive patients 
with severe chronic kidney disease. One of the first re-
ports was made by Stock et al.13, from the University of 
California. To become eligible for kidney transplantation, 
HIV-positive patients had to fulfill the following criteria: 
undetectable viral load (negative HIV-RNA in plasma) for 
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three months, CD4+ T cell counts > 200 cells/mm3 for six 
months, and neither opportunistic infection nor carcino-
ma. Ten patients undergoing kidney transplantation were 
included. At 36-month follow-up, all of them were alive 
and had a functioning graft. The kidney graft rejection rate 
was 50%. All of the patients were maintained on HAART. 
Viral load remained undetectable in all patients and CD4 
cell counts remained stable. These results were encoura-
ging to indicate kidney transplantation as a treatment op-
tion in HIV-positive patients with well-controlled disease. 
There were several other reports strengthening this treat-
ment alternative (Table 1).
In 2003, Roland et al.14 reviewed 26 seropositive pa-
tients receiving kidney transplantation. Survival rates for 
the patient (92%) and the graft (85%) in 10 months were 
comparable to HIV-negative patient rates. The rejection 
rate in HIV-infected patients was 37%. The review of the 
USRDS registry data for deceased donor kidney trans-
plantation in the period 1996 to 2001 showed that from 
27,851 patients with available HIV serology only 47 pa-
tients (0.2%) were HIV-positive. From these, 12.8% were 
black. HIV-positive patient survival rate after three years 
was 95%. Only 2 HIV-positive patients died (4.3%), com-
pared to 12.8% in the HIV-negative group. These good re-
sults might have been infiuenced by stricter criteria from 
transplanting centers in selecting HIV-positive recipients 
for kidney transplantation. Another possible bias in this 
review might have been the increased use of immunosup-
pressive induction therapy in seropositive recipients.
 From these results, the authors proposed kidney trans-
plantation in HIV-positive patients as a more viable treat-
ment strategy after HAART era advent.
In a prospective study, Kumar et al.2 studied 40 HIV-
-positive kidney transplanted subjects. Inclusion criteria 
were similar to those described by Stock et al.13 (negative 
HIV-RNA, viral load < 400 copies/mL, and absolute CD4+ 
cell count > 200 cells/mm3). The results showed that pa-
tient survival rate over first and second post-transplanta-
 
Authors n Follow-up time (months) Patient survival Graft survival
before HAART
Tzakis et al.10 
(1990)
5 36 80% 80%
Erice et al.9 
(1991)
11 30 64% 54%
Swanson et al.11 
(USRDS data) 
(2002)
32 60 71% 44%
after HAART
Stock et al.13 
(2003)
10 16 100% 100%
Roland et al.14 
(2003)
29 10 92% 85%
Abbott et al.15 
(USRDS data) 
(2004)
47 36 95% 97.3%
Kumar et al.2 
(2005)
40 24 82% 71%
Qiu et al.16 
(UNOS data) 
(2006)
38 60 91.3% 76.1%
Roland et al.19 
(2008)
18 36 94% 83%
Gruber et al.18 
(2008)
8 15 100% 88%
Locke et al.17 
(UNOS data) 
(2009)
100 12 95.4% 87.9%
USRDS, United States Renal Data System; UNOS, United Network for Organ Sharing.
Table 1 – Patient and kidney graft survival in positive-HIV patients undergoing kidney transplantation
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tion years was 85% and 82%, respectively, similar to results 
obtained from other high risk patient groups and larger 
than survival rate in HIV-positive patients on dialysis.
Qiu et al.16 analyzed kidneys from the same deceased 
donor transplanted to HIV-positive or HIV-negative pa-
tients, these data were obtained from United Network for 
Organ Sharing (UNOS) from 1997 to 2004. Thirty-eight 
HIV-positive patients and 38 HIV-negative patients recei-
ving kidneys from the same donors were included in this 
analysis. Although the results were statistically non-signi-
ficant, the patient and graft survival rate was higher in the 
HIV-positive group, compared to the HIV-negative group.
More recently, Locke et al.17, at John Hopkins Medi-
cal Hospital, have analyzed 39,501 kidney transplanted 
patients from the UNOS registry from 2004 to 2006 and 
they showed that  although patient survival is similar in 
HIV-positive and HIV-negative, graft survival was signi-
ficantly lower in HIV-positive cases (87.9% vs 94.6% in 
HIV-positive).
A group from University of Detroit evaluated the in-
® uence of HIV-positive recipient characteristics on kidney 
transplantation and reported a clinical course analysis of 
eight kidney transplanted seropositive patients with other 
poor prognosis factors, such as coinfection with hepatitis 
C virus and immune sensitization over a mean time of 15 
months. The survival rates found were 100% for the pa-
tient and 88% for the graft at the end of the period. In this 
study, only one patient developed acute rejection (13%)18.
On the other hand, high acute rejection rates in HIV-
-positive transplanted subjects were described by Roland 
et al.19 in a study assessing 18 patients undergoing kidney 
transplantation. The authors described a 52% acute rejec-
tion incidence over the first-year follow-up and 73% in 
three years, which is consistent with the results previously 
found by et al. in 2003.
There are no specific registries about transplantation 
activity in HIV-positive patients in Brazil. Recently, we 
have performed a kidney transplantation in a 61-year-old 
patient presenting with a chronic kidney disease seconda-
ry to polycystic kidney disease; he had been infected with 
HIV seven years before the transplantation20. At the time 
of HIV infection diagnosis, the patient received antiretro-
viral therapy with zidovudine (AZT®, AstraZeneca) 600 
mg/day, 3Tc (lamivudine; Epivir®, GlaxoSmith) 75 mg/
day and atazanavir (Reyataz®, Bristol-Myers Squibb) 400 
mg/day. He was responsive to the therapy and, six mon-
ths after starting it, he had undetectable viral load, which 
was maintained throughout evolution. CD4+ lymphocyte 
counts was also kept above 500 cells/mm3. In the course 
of the disease, the patient presented with end-stage renal 
disease, for which he had been receiving treatment with 
hemodialysis for the last five and a half years. At the trans-
plantation time, his HIV-RNA was negative and CD4+ 
lymphocyte count was 464 cells/mm3. Kidney transplanta-
tion performed with live donor was uneventful and the pa-
tient showed an immediate reduction in serum creatinine.
The immunosuppressive regimen included basiliximab 
(Simulect®, Novartis) as inducing drug and cyclosporine 
(Sandimmun®, Novartis), sirolimus (Rapamune®, Wyeth), 
and prednisone as maintenance drugs. Although the pa-
tient had been given only half the usual doses of cyclos-
porine and sirolimus, he had blood levels extremely high. 
Trough concentration was 1,131 ng/mL for cyclosporine 
and 56.1 ng/mL for sirolimus 6 days after using the drugs, 
with  dosage being adjusted to 25% of usual dosage. Cur-
rently, two years after kidney transplantation, the patient 
is well, with good kidney graft function, undetectable viral 
load, and CD4+ lymphocyte count of 645 cells/mm3.
Regarding HAART era benefits, kidney transplanta-
tion in HIV-infected patients is considered an alternative 
treatment,  which tends to occur more frequently in clini-
cal practice.
In view of this new reality,  establishing criteria for or-
gan transplantation practice in this population is required. 
Recently, based on major impact studies on kidney trans-
plantation in HIV-infected patients, Bhagani et al.8 have 
gathered the main recommendations to consider a patient 
as a receptor candidate (Table 2). 
Table 2 – Selection criteria in HIV-positive patients for 
kidney transplantation 
tCD4+ lymphocyte count > 200 cells/mm3 for at least 6 
months
tUndetectable viral load (< 50 RNA copies/mL) for at 
least 6 months
t Treatment using HAART for at least 6 months
tNo AIDS-defining diseases following HAART start
HIV AND IMMUNOSUPPRESSION IN KIDNEY TRANSPLANTATION
Overall, immunosuppressive drug use in organ transplan-
tations in HIV-infect patients has proven to be e® ective 
and safe, since some of these drugs also have an antire-
troviral action. Because of drug-drug interaction betwe-
en some HAART drugs and immunosuppressive agents, 
blood level monitoring of immunosuppressive drugs 
should be done more often, with dosage adjustments whe-
never necessary21.
IMMUNOSUPPRESSIVE DRUG ANTIRETROVIRAL EFFECT
For many years had HIV infection been considered a con-
traindication to organ transplantation based on a principle 
that, in the presence of immunosuppression, there would be 
an environment favoring viral replication. However, more 
recently, studies have demonstrated that some of the immu-
nosuppressive drugs used in transplantation, such as calci-
neurin inhibitors (cyclosporine and tacrolimus), sirolimus, 
and mycophenolic acid, exhibit antiretroviral action.
MORENO CN ET AL.
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Cyclosporine is a calcineurin inhibitor with proper-
ties able to inhibit HIV replication. This eect is a result 
of cyclosporine binding to cyclophilin A, preventing the 
formation of protein p55Gag/cyclophilin complex, requi-
red for HIV maturation and replication. HIV is known 
to replicate only in activated CD4 T cells. Considering 
cyclosporine inhibits T cell activation via IL-2 inhibition, 
this drug can reduce activated CD4 T cell number, thus 
reducing CD4+ T cell pool available to viral replication22. 
Cyclosporine possibly has an antiapoptotic eect on 
CD4+ T lymphocyte, as demonstrated by Groux et al.23 
In this study, T lymphocyte apoptosis was prevented by 
cyclosporine A in peripheral blood samples from HIV-
-positive subjects in vitro.
Tacrolimus action as a antiretroviral drug was shown 
in few studies. Tacrolimus action inhibiting viral prolife-
ration was described by Briggs et al.24 in HIV-chronically 
infected cells.
Sirolimus is an immunomodulation-acting immuno-
suppressive drug inhibiting mTOR (mammalian target 
of rapamycin). The drug can reduce CCR5 viral co-re-
ceptor expressed in T lymphocytes and monocytes at a 
transcriptional level. CCR5 receptor is essential for HIV 
transmission and replication,  as evidenced by the fact 
that individuals not expressing this protein proved to be 
resistant to HIV infection.
Azatioprin use has been associated with increased vi-
ral replication, while the opposite seems  to happen with 
the use of mycophenolate mofetil26. The mycophenolic 
acid prodrug mycophenolate mofetil (MMF) is another 
immunosuppressive drug showing antiretroviral eect. 
The drug seems to have synergistic activity on the nucle-
oside analog reverse transcriptase inhibitors, one of the 
classical components used in HIV infection treatment 
regimen. This synergism results from desoxyguanosine-
-triphosfate, an intracellular enzyme essential for HIV 
replication27.
Izzedine et al.26 showed prednisolone increases CD4+ 
T lymphocyte population. Another study showed pred-
nisolone acts by suppressing HIV viral load and inhibi-
ting CCL2, a proinammatory cytokine induced by HIV 
infection28.
As for the use of either monoclonal or polyclonal an-
ti-CD3 antibodies, it is worth noting it is not recommen-
ded in HIV-positive patients. It is a powerful immunosu-
ppressive drug capable of inducing CD4+ T lymphocyte 
depletion, increasing the risk of disease progression, as 
well as opportunistic infection development29.
DRUG INTERACTIONS BETWEEN IMMUNOSUPPRESSIVE AGENTS 
AND HAART
Concurrent use of immunosuppressive and antiretroviral 
drugs is required in an organ transplantation setting in 
HIV-positive recipients. Complex pharmacokinetic and 
pharmacodynamic interactions between these drugs are 
described in literature and therapeutic level strict moni-
toring is required both to keep HIV infection controlled 
and to avoid rejection and toxicity by immunosuppres-
sive drugs.
The most classical interactions are found between 
common protease inhibitors used to treat HIV-positive 
patients and calcineurina inhibitors (cyclosporine and 
tacrolimus) or mTOR inhibitors (sirolimus and everoli-
mus). This interaction results from the fact both protease 
inhibitors and immunosuppressive drugs previously des-
cribed are metabolized via P450 cytochrome, contribu-
ting to increasing immunosuppressive blood levels30. In 
literature, HIV-positive patients are suggested to initiate 
calcineurin inhibitors four weeks before transplantation 
(in case of living donor transplantation), monitoring 
drug levels to pre-transplant setting. This management 
aims to enable transplantation in the presence of immu-
nosuppressants therapeutic levels, minimizing the risk of 
toxicity or, less frequently, underexposure to the drug8.
 Given the pharmacological interactions that pro-
mote increased blood levels of calcineurin inhibitors 
and mTOR inhibitors, we must emphasize the elevated 
risk of toxicity of these drugs, including the possibility 
of thrombotic microangiopathy development. Throm-
botic microangipathy is a histological manifestation of 
hemolytic-uremic syndrome, occurring as a post-trans-
plantation complication in an incidence ranging from 
0.8% to 14% kidney transplantations. We should add to 
this the fact that HIV infection is a proven risk factor 
for thrombotic microangiopathy development31. Re-
cently, cases of hemolytic-uremic syndrome associated 
with sirolimus use were reported20,32, possibly resulting 
from reduced VEGF (an important factor in maintai-
ning vascular endothelium viability) expression indu-
ced by sirolimus33. Furthermore, there is evidence that 
high sirolimus blood levels associated with cyclospori-
ne also contribute to the thrombotic microangiopathy 
pathogenesis34.
Sodium mycophenolate20 and mycophenolate mofe-
til21 are considered safe immunosuppressive alternati-
ves for kidney transplantation in HIV-positive patients, 
as they have few interactions with other common drugs 
used in HAART. However, diarrhea, a well-known myco-
phenolate side eect, may hinder its use  in clinical prac-
tice, since it can be added to the diarrheal eects of an-
tiretroviral drugs and the disease itself in these patients.
 Despite the increasing need for association between 
immunosuppressants and antiretroviral drugs in cur-
rent clinical practice, there are few studies to guide the 
safe use of these drugs combined.  Potential drug in-
teractions between the main immunosuppressive drugs 
used in organ transplantation setting and major antire-
troviral drugs are shown in Table 3.
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CONCLUSION
HIV-seropositivity is no longer absolutely contraindicated 
in kidney transplantation, but it is currently a relative con-
traindication35. Nevertheless, there are still few reports on 
transplantation in this population.
In summary, although some studies show a trend to-
wards higher graft rejection rates in HIV-positive patients, 
literature data suggests kidney transplantation following 
specific selection criteria seems to be a safe alternative to 
renal replacement therapy in this group.
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